Hydroxychloroquine (Indication Antiphospholipid Syndrom)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)0.39 [0.03, 4.81]0%2 studies1149not evaluable ROB-

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Small for gestational age (weight)0.42 [0.18, 0.99]2%3 studies33216not evaluable ROB4.18 [.; 1.10]
Preterm (< 37 weeks)0.45 [0.09, 2.11]71%2 studies56146not evaluable ROB-
Low birth weight (< 2500g)0.42 [0.22, 0.83]-1 study47112not evaluable ROB4.14 [.; 1.69]
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preeclampsia0.32 [0.14, 0.70]0%4 studies46241not evaluable ROB5.72 [.; 2.20]
Caesarean0.50 [0.29, 0.86]0%2 studies6682not evaluable ROB3.43 [.; 1.58]
Maternal consequences (as a whole)0.32 [0.14, 0.72]-1 study3594not evaluable ROB5.77 [.; 2.10]
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Low Apgar score (< 7) (at 5 min)0.38 [0.19, 0.75]-1 study2233not evaluable ROB4.70 [.; 1.98]
4 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Intrauterine deaths (as a whole or unspecified)0.37 [0.21, 0.65]56%7 studies493437not evaluable ROB4.89 [.; 2.44]
Early intrauterine death (< 22 weeks)0.29 [0.09, 0.95]79%3 studies110246not evaluable ROB6.44 [.; 1.29]
1 non statistically significant endpoints reported in only one study